RESEARCH SUMMARY

Triple combination therapy lowered HbA1c more than dual therapy in type 2 diabetes

Moderate confidence
Some Concerns bias
Last updated May 6, 2026

Key takeaway:

In Indian adults with type 2 diabetes not controlled on metformin alone, the fixed-dose triple combination of glimepiride, voglibose, and extended-release metformin lowered HbA1c more than either dual combination over 24 weeks, with few mild side effects.

Study at a glance

Study type

RCTs

duration

Medium-Term (3–12 mo)

Intervention

Glimepiride + voglibose + metformin, Voglibose + metformin, Metformin + glimepiride

Outcomes

HbA1c, Fasting Plasma Glucose, Postprandial glucose, Hypoglycemia events, Adverse events incidence, HbA1c, Fasting Plasma Glucose, Postprandial glucose, Hypoglycemia events, Adverse events incidence, HbA1c, Fasting Plasma Glucose, Postprandial glucose, Hypoglycemia events, Adverse events incidence

Funding

Industry sponsored

What was studied

Whether a fixed-dose triple oral therapy improves glycemic control more than dual therapy

What they found

  • HbA1c ↓ by 1.57% at 24 weeks with triple therapy
  • More patients reached HbA1c <7% with triple therapy
  • Fasting glucose ↓ in all treatment groups
  • Postprandial glucose ↓ in all treatment groups
  • Hypoglycemia ↔ rare and no severe events were reported

mainEffects

HbA1c ↓ by 1.57% at 24 weeks with triple therapy

More patients reached HbA1c <7% with triple therapy

Fasting glucose ↓ in all treatment groups

Postprandial glucose ↓ in all treatment groups

Hypoglycemia ↔ rare and no severe events were reported

Evidence Suggest

  • HbA1c fell more with glimepiride plus voglibose plus extended-release metformin than with either dual-drug comparator at both 12 and 24 weeks.
  • By 24 weeks, 62.3% of patients on triple therapy reached HbA1c below 7%, compared with 30.0% and 35.7% in the dual-therapy groups.
  • Only two level 1 hypoglycemia events were reported overall, and no serious or severe adverse events occurred.

Who this applies to

These findings apply most directly to adults aged 18 to 65 years with type 2 diabetes in India who remain above target despite stable metformin monotherapy, and who do not have major renal, hepatic, or gastrointestinal exclusion conditions. The results are most relevant to patients with HbA1c between 7.5% and 9.0%.

Keep in Mind

All three treatments improved glucose control, so the main question is the size of the extra benefit from the triple combination. The primary endpoint was an objective lab measure, which strengthens confidence, but the open-label design and industry funding still matter. The study also used fixed-dose combinations and dose uptitration rules that may not fully match every real-world setting.

Between the Lines

  • The study was open-label, so participants and clinicians knew which treatment was given.
  • The trial included only adults in India with baseline HbA1c up to 9%, so results may not apply to all people with type 2 diabetes.
  • Follow-up lasted 24 weeks, so longer-term durability and safety are still uncertain.
  • The study was funded by the manufacturer, which increases the need for independent confirmation.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Sources

guidelines

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025

This ADA guideline outlines how to intensify drug treatment in adults with type 2 diabetes, including when combination therapy is appropriate after metformin alone is not enough.
guidelines

Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and the EASD

This consensus report explains why combination therapy can be useful when HbA1c remains above target and gives context for comparing triple versus dual oral treatment strategies.
guidelines

Standards of Care in Diabetes—2024

Annual ADA clinical practice guideline issue covering broad diabetes management.
guidelines

Type 2 diabetes in adults: management

NICE clinical guideline for adult type 2 diabetes management.
guidelines

A Guide for People with Type 2 Diabetes | American Diabetes Association

American Diabetes Association resource matched by keyword relevance (type 2 diabetes)
guidelines

Diabetes Diagnosis & Tests | ADA

Learn about the diabetes diagnosis criteria and various tests used like A1C, Fasting Plasma Glucose (FPG), Oral Glucose Tolerance Test (OGTT), and Random Plasma Glucose Test.
guidelines

Diabetes in America: Prevalence, Statistics, and Economic Impact

Explore the latest diabetes in America data, including type 2 diabetes statistics, prevalence by age and ethnicity, death rates, and the financial burden of diabetes in the U.S.
expertInsights

Type 2 diabetes - Diagnosis and treatment

This Mayo Clinic overview gives practical context on common diabetes medicines, treatment escalation, and the balance between glucose control, side effects, and convenience.
studiesGroup

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

2026
studiesGroup

Efficacy and Safety of a Diabetic Low Glycemic Load Kit With Standard Care in Patients With Type 2 Diabetes: An Open-Label Randomized Pilot Study.

2026
studiesGroup

Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis.

2026
studiesGroup

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.

2026
studiesGroup

The role of peripheral blood HIF-1α in pancreatic β-cell dysfunction and insulin resistance among patients with type 2 diabetes: a systematic review and meta-analysis.

2026

No ads. No tracking

A clean, privacy-first research experience.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.